[go: up one dir, main page]

MA28795B1 - Amines polycycliques aryle-substituées, leur procédé de fabrication, et leur utilisation en tant que médicament - Google Patents

Amines polycycliques aryle-substituées, leur procédé de fabrication, et leur utilisation en tant que médicament

Info

Publication number
MA28795B1
MA28795B1 MA29673A MA29673A MA28795B1 MA 28795 B1 MA28795 B1 MA 28795B1 MA 29673 A MA29673 A MA 29673A MA 29673 A MA29673 A MA 29673A MA 28795 B1 MA28795 B1 MA 28795B1
Authority
MA
Morocco
Prior art keywords
medicaments
aryl
manufacture
substituted polycyclic
polycyclic amines
Prior art date
Application number
MA29673A
Other languages
English (en)
Inventor
Lothar Schwink
Siegfried Stengelin
Matthias Gossel
Gerhard Hessler
Petra Lennig
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MA28795B1 publication Critical patent/MA28795B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
MA29673A 2004-08-16 2007-02-08 Amines polycycliques aryle-substituées, leur procédé de fabrication, et leur utilisation en tant que médicament MA28795B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004039789A DE102004039789A1 (de) 2004-08-16 2004-08-16 Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
MA28795B1 true MA28795B1 (fr) 2007-08-01

Family

ID=35610053

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29673A MA28795B1 (fr) 2004-08-16 2007-02-08 Amines polycycliques aryle-substituées, leur procédé de fabrication, et leur utilisation en tant que médicament

Country Status (28)

Country Link
US (5) US7838547B2 (fr)
EP (2) EP1781656B1 (fr)
JP (2) JP2008509958A (fr)
KR (2) KR20070046868A (fr)
CN (2) CN101006089A (fr)
AR (2) AR050603A1 (fr)
AT (1) ATE381564T1 (fr)
AU (2) AU2005274315A1 (fr)
BR (2) BRPI0514404A (fr)
CA (2) CA2577261A1 (fr)
CY (1) CY1108077T1 (fr)
DE (2) DE102004039789A1 (fr)
DK (1) DK1781656T3 (fr)
ES (1) ES2297758T3 (fr)
IL (2) IL181007A0 (fr)
MA (1) MA28795B1 (fr)
MX (2) MX2007001584A (fr)
MY (1) MY145133A (fr)
NO (1) NO20071271L (fr)
PE (2) PE20060626A1 (fr)
PL (1) PL1781656T3 (fr)
PT (1) PT1781656E (fr)
RU (1) RU2007109600A (fr)
SI (1) SI1781656T1 (fr)
TW (2) TW200621781A (fr)
UY (2) UY29071A1 (fr)
WO (2) WO2006018279A2 (fr)
ZA (1) ZA200700354B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004039789A1 (de) * 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2582327A1 (fr) * 2004-10-01 2006-04-13 Takao Suzuki Compose heterocyclique azote substitue en 2 par un groupement arylcarboxamide
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7728031B2 (en) * 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
CA2649043C (fr) * 2006-04-19 2013-09-17 Astellas Pharma Inc. Derive d'azolecarboxamide
DE102006021874B4 (de) * 2006-05-11 2008-03-27 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-amino substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
RS20090154A (sr) 2006-10-18 2010-10-31 Pfizer Products Inc. Jedinjenja biaril etra uree
US8158643B2 (en) 2006-12-05 2012-04-17 Janssen Pharmaceutica N.V. Substituted diaza-spiro-pyridinone derivatives for use in MCH-1 mediated diseases
US8383852B2 (en) * 2007-02-16 2013-02-26 Emisphere Technologies, Inc. Compounds having a cyclic moiety and compositions for delivering active agents
WO2008109285A1 (fr) 2007-03-06 2008-09-12 Allergan, Inc. Procédés de traitement de troubles cognitifs
NZ580266A (en) 2007-04-27 2012-03-30 Purdue Pharma Lp Trpv1 inhibitors / antagonists and uses thereof
CL2008001822A1 (es) * 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
WO2009036132A1 (fr) 2007-09-11 2009-03-19 Abbott Laboratories N-oxydes d'octahydro-pyrrolo[3,4-b]pyrrole
DK2206707T3 (da) 2007-10-24 2014-08-11 Astellas Pharma Inc Azolcarboxamidforbindelse eller salt deraf
EP2310372B1 (fr) 2008-07-09 2012-05-23 Sanofi Composés hétérocycliques, leur procédé de préparation, médicaments les contenant et leur utilisation
KR101955651B1 (ko) * 2008-08-22 2019-03-07 사우디 아람코 테크놀로지스 컴퍼니 촉매 및 중합체 합성방법
CN102282132A (zh) * 2008-11-19 2011-12-14 先灵公司 二酰基甘油酰基转移酶的抑制剂
RU2011126215A (ru) * 2008-11-26 2013-01-10 Эбботт Лэборетриз НОВЫЕ ЗАМЕЩЕННЫЕ ОКТАГИДРОЦИКЛОПЕНТА[c]ПИРРОЛ-4-АМИНЫ В КАЧЕСТВЕ БЛОКАТОРОВ КАЛЬЦИЕВЫХ КАНАЛОВ
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
UA104447C2 (uk) 2008-12-19 2014-02-10 Сіртріз Фармасьютікалз, Інк. Тіазолопіридинові сполуки, що модулюють сиртуїн
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
WO2011149995A1 (fr) 2010-05-25 2011-12-01 Abbott Laboratories Nouvelles octahydrocyclopenta[c]pyrrol-4-amines substituées comme bloqueurs de canaux calciques
WO2011149993A2 (fr) 2010-05-25 2011-12-01 Abbott Laboratories Octahydrocyclopenta [c] pyrroles substitués utilisés en tant que modulateurs des canaux calciques
EP2576532B1 (fr) 2010-06-07 2018-07-18 Novomedix, LLC Composés furanyliques et leur utilisation
EP2642998B1 (fr) 2010-11-24 2020-09-16 The Trustees of Columbia University in the City of New York Antagoniste rbp4 non rétinoïde pour le traitement de la dégénérescence maculaire liée à l'âge et de la maladie de stargardt
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
EP2683700B1 (fr) 2011-03-08 2015-02-18 Sanofi Dérivés d'oxathiazine tétra-substitués, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
EP2683705B1 (fr) 2011-03-08 2015-04-22 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683699B1 (fr) 2011-03-08 2015-06-24 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
LT2723732T (lt) 2011-06-22 2017-02-27 Purdue Pharma Lp Trpv1 antagonistai, įskaitant dihidroksi pakaitą, ir jų panaudojimas
RU2671496C2 (ru) 2013-10-14 2018-11-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные 5-пиперидин-8-цианохинолина
WO2015057659A1 (fr) 2013-10-14 2015-04-23 Eisai R&D Management Co., Ltd. Composés de quinoline sélectivement substitués
US10987322B2 (en) 2014-06-06 2021-04-27 Flexus Biosciences, Inc. Immunoregulatory agents
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
UY36391A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
CN107205970A (zh) 2014-11-05 2017-09-26 弗莱塞斯生物科学公司 免疫调节剂
CR20180443A (es) 2016-03-17 2018-11-21 Hoffmann La Roche Derivado de morfolina
AR111295A1 (es) 2017-03-20 2019-06-26 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
IL310346A (en) 2017-10-20 2024-03-01 Univ Vanderbilt Muscarinic acetylcholine M4 receptor antagonists
JP2021503443A (ja) 2017-10-31 2021-02-12 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
JP7352294B2 (ja) 2018-02-02 2023-09-28 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (fr) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activation de la pyruvate kinase r
RS67259B1 (sr) 2019-09-19 2025-10-31 Novo Nordisk Healthcare Ag Kompozicije koje aktiviraju piruvat kinazu r (pkr)
ES2970315T3 (es) * 2020-07-31 2024-05-28 Abarceo Pharma Ab Nuevos inhibidores del VDAC1
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CN113845427B (zh) * 2021-09-07 2024-06-25 华东师范大学 芳基醇、芳基酮、芳基羧酸化合物及其合成方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9314973D0 (en) 1993-07-20 1993-09-01 Smithkline Beecham Plc Medicaments
WO2000053591A1 (fr) 1999-03-08 2000-09-14 Bayer Aktiengesellschaft Derives de la thiazolyluree et leur utilisation comme antiviraux
AU7315700A (en) 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Melanin concentrating hormone antagonist
PL211888B1 (pl) * 1999-11-26 2012-07-31 Shionogi & Co Związek będący antagonistą NPY Y5 oraz kompozycja farmaceutyczna zawierająca taki związek
DK1257550T3 (da) * 2000-02-04 2006-03-27 Portola Pharm Inc Blodplade-ADP-receptor-inhibitor
AU7320701A (en) 2000-07-05 2002-01-14 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
EP1299362A4 (fr) 2000-07-05 2004-11-03 Synaptic Pharma Corp Antagonistes selectifs des recepteurs (mch1) d'hormone-1 de concentration de la melanine et utilisation de ceux-ci
KR20030059084A (ko) * 2000-07-31 2003-07-07 스미스크라인 비참 피.엘.시. 카르복사미드 화합물 및 이것의 사람 11ｃｂｙ 수용체의길항제로서의 용도
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
CA2443697A1 (fr) * 2001-04-13 2002-10-24 Pier F. Cirillo Composes benzo-fusionnes a disubstitution en positions 1,4
AU2002305323A1 (en) 2001-05-04 2002-11-18 Tularik Inc. Fused heterocyclic compounds
DE10139416A1 (de) * 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2003035624A1 (fr) 2001-10-25 2003-05-01 Takeda Chemical Industries, Ltd. Compose quinoline
AU2002352878B2 (en) * 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
AU2003226927A1 (en) 2002-04-09 2003-10-27 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
JP2005529923A (ja) 2002-05-13 2005-10-06 イーライ・リリー・アンド・カンパニー 肥満および糖尿病の治療におけるメラニン凝集ホルモンアンタゴニストとして使用するための多環式化合物
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
TW200510311A (en) * 2002-12-23 2005-03-16 Millennium Pharm Inc CCr8 inhibitors
GB0320244D0 (en) * 2003-05-06 2003-10-01 Aventis Pharma Inc Pyrazoles as inhibitors of tumour necrosis factor
AU2004253267B2 (en) * 2003-07-03 2008-12-04 F. Hoffmann-La Roche Ag Dual NK1/NK3 antagonists for treating schizophrenia
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
PL1781656T3 (pl) 2008-03-31
ES2297758T3 (es) 2008-05-01
IL181007A0 (en) 2007-07-04
KR20070046868A (ko) 2007-05-03
ATE381564T1 (de) 2008-01-15
JP2008509957A (ja) 2008-04-03
EP1781663B1 (fr) 2013-11-20
EP1781656A2 (fr) 2007-05-09
MY145133A (en) 2011-12-30
PT1781656E (pt) 2008-02-01
CN101006091A (zh) 2007-07-25
US7838547B2 (en) 2010-11-23
AU2005274315A1 (en) 2006-02-23
JP2008509958A (ja) 2008-04-03
UY29072A1 (es) 2006-03-31
EP1781656B1 (fr) 2007-12-19
US20100298378A1 (en) 2010-11-25
ZA200700354B (en) 2008-06-25
DK1781656T3 (da) 2008-05-05
AR050603A1 (es) 2006-11-08
MX2007001584A (es) 2007-04-20
RU2007109600A (ru) 2008-09-27
BRPI0514404A (pt) 2008-06-10
US8586609B2 (en) 2013-11-19
WO2006018279A2 (fr) 2006-02-23
CY1108077T1 (el) 2014-02-12
KR20070053225A (ko) 2007-05-23
CA2577255A1 (fr) 2006-02-23
WO2006018280A2 (fr) 2006-02-23
US8163741B2 (en) 2012-04-24
SI1781656T1 (sl) 2008-04-30
CN101006089A (zh) 2007-07-25
TW200621780A (en) 2006-07-01
DE502005002316D1 (de) 2008-01-31
NO20071271L (no) 2007-03-16
DE102004039789A1 (de) 2006-03-02
PE20060497A1 (es) 2006-07-17
US20070197584A1 (en) 2007-08-23
BRPI0514365A (pt) 2008-06-10
EP1781663A2 (fr) 2007-05-09
US20090258881A1 (en) 2009-10-15
IL181008A0 (en) 2007-07-04
US20070299077A1 (en) 2007-12-27
US20090258872A1 (en) 2009-10-15
WO2006018279A3 (fr) 2006-05-11
PE20060626A1 (es) 2006-08-08
WO2006018280A3 (fr) 2006-05-11
US8357686B2 (en) 2013-01-22
MX2007001478A (es) 2007-04-19
CN101006091B (zh) 2010-09-15
UY29071A1 (es) 2006-03-31
AU2005274314A1 (en) 2006-02-23
CA2577261A1 (fr) 2006-02-23
TW200621781A (en) 2006-07-01
AR050604A1 (es) 2006-11-08
US7569583B2 (en) 2009-08-04

Similar Documents

Publication Publication Date Title
MA28795B1 (fr) Amines polycycliques aryle-substituées, leur procédé de fabrication, et leur utilisation en tant que médicament
EP2272876A4 (fr) Glucane et mannane, leur procédé de fabrication et leur utilisation
EP2123260A4 (fr) Composition de liposome et son procédé de préparation
EP2010127A4 (fr) Composition contenant des charges, son procede de fabrication et son utilisation
EP2265591A4 (fr) Composés de nitrone, procédé de préparation de ceux-ci, et utilisation de ceux-ci dans la fabrication de médicaments
ATE459623T1 (de) Pyridoä2,3-düpyrimidine, die sich als hcv- inhibitoren eignen und verfahren zu deren herstellung
EP2088160A4 (fr) Microsphère polymère supermacroporeuse et son procédé de préparation
EP2247623A4 (fr) Nouveaux dérivés de cellulose, leur procédé de fabrication et leur utilisation
ATE444334T1 (de) Polyolefinverbindungen, daraus hergestellte artikel und herstellungsverfahren dafür
EP2219782A4 (fr) Catalyseurs mixtes de manganèse-ferrite, leur procédé de fabrication et procédé de fabrication de 1,3-butadiène l'utilisant
EP2311585A4 (fr) Brame coulée en continu et procédé pour sa production
DE602005007283D1 (de) Vollgummireifen und Verfahren zu dessen Herstellung
EP2247528A4 (fr) Nanodispositif, transistor comprenant le nanodispositif, procédé pour fabriquer le nanodispositif, et procédé pour fabriquer le transistor
EP2292242A4 (fr) Dérivé de scutellarine, procédé d'élaboration, composition pharmaceutique, et utilisation correspondante
EP2077593A4 (fr) Séparateur de batterie alcaline, procédé de production de celui-ci et batteries alcalines
EP2285881A4 (fr) Billes polymères à base de microgel et leur procédé de préparation
EP2471883A4 (fr) Composition adhésive à base d'eau, son procédé de fabrication, et film adhésif
BR112012002403A2 (pt) polímero supramolecular, processo de síntese de polímero supramolecular, composição e artigos
EP2366691A4 (fr) Nitropyridinyléthylèneimine, composition pharmaceutique l'incluant, sa méthode de synthèse et ses applications
BRPI0821708A2 (pt) Processo para obter fluorometil 1,1,1,3,3,3-hexa-fluorisopropil éter purificado
BRPI0718999A2 (pt) Pirazois substituídos, composições que os contêm, processo de produção e utilização
EP2036889A4 (fr) Indoles substitués et procédé de production et d'utilisation de ceux-ci
ATE462408T1 (de) Pharmazeutische zusammensetzungen, enthaltend valatograst, und verfahren zu deren herstellung
DE602005025184D1 (de) Harzzusammensetzung, Formkörper daraus und dessen Herstellungsverfahren
EP2333547A4 (fr) Microbilles et leur procédé de préparation